Hutchmed's Fruquintinib Granted New Drug Application Priority Review by US FDA
26 May 2023 - 05:06PM
Dow Jones News
By Anthony O. Goriainoff
Hutchmed (China) said Friday that its fruquintinib cancer
treatment has been granted a priority review of the New Drug
Application by the U.S. Food and Drug Administration.
The London-listed biopharmaceutical company said that if
approved fruquintinib will be the first and only highly selective
inhibitor of all three vascular endothelial growth factor receptors
approved in the U.S. for previously treated metastatic colorectal
cancer.
Hutchmed said the FDA plans to complete the review process by
Nov. 30.
Fruquintinib is approved in China as a treatment for refractory
metastatic colorectal cancer, the company said.
"Today's acceptance marks a significant advancement towards the
goal of providing patients with previously treated metastatic
colorectal cancer a much-needed therapeutic option, given the
limited treatment options currently available to patients," the
company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
May 26, 2023 02:51 ET (06:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From May 2023 to Jun 2023
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Jun 2022 to Jun 2023
